Altered Adipokine Expression in Tumor Microenvironment Promotes Development of Triple Negative Breast Cancer.
TNBC
adipokines
adipose
cytokines
triple negative breast cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
26 Aug 2022
26 Aug 2022
Historique:
received:
25
07
2022
revised:
23
08
2022
accepted:
24
08
2022
entrez:
9
9
2022
pubmed:
10
9
2022
medline:
10
9
2022
Statut:
epublish
Résumé
Obesity is a remarkably important factor for breast carcinogenesis and aggressiveness. The implication of increased BMI in triple negative breast cancer (TNBC) development is also well established. A malignancy-promoting role of the adipose tissue has been supposed, where the adipocytes that constitute the majority of stromal cells release pro-inflammatory cytokines and growth factors. Alterations in adipokines and their receptors play significant roles in breast cancer initiation, progression, metastasis, and drug response. Classic adipokines, such as leptin, adiponectin, and resistin, have been extensively studied in breast cancer and connected with breast cancer risk and progression. Notably, new molecules are constantly being discovered and the list is continuously growing. Additionally, substantial progress has been made concerning their differential expression in association with clinical and pathological parameters of tumors and the prognostic and predictive value of their dysregulation in breast cancer carcinogenesis. However, evidence regarding the mechanisms by which adipose tissue is involved in the development of TNBC is lacking. In the present article we comment on current data on the suggested involvement of these mediators in breast cancer development and progression, with particular emphasis on TNBC, to draw attention to the design of novel targeted therapies and biomarkers.
Identifiants
pubmed: 36077676
pii: cancers14174139
doi: 10.3390/cancers14174139
pmc: PMC9454958
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
J Obes. 2019 Mar 25;2019:3820759
pubmed: 31019808
Cancer Res. 2019 Jul 1;79(13):3347-3359
pubmed: 30940661
Eur J Pharmacol. 2002 Apr 12;440(2-3):213-21
pubmed: 12007537
Life Sci. 2022 Sep 1;304:120704
pubmed: 35714703
Front Endocrinol (Lausanne). 2021 Jun 18;12:690484
pubmed: 34220716
Biochem Biophys Res Commun. 1999 Apr 2;257(1):79-83
pubmed: 10092513
Cell Rep. 2019 Dec 24;29(13):4389-4406.e10
pubmed: 31875548
FEBS Lett. 2008 Jan 9;582(1):74-80
pubmed: 18054335
Int J Cancer. 2007 Aug 15;121(4):856-62
pubmed: 17397032
Crit Rev Oral Biol Med. 2000;11(3):279-303
pubmed: 11021631
Diabetologia. 2012 Jun;55(6):1607-18
pubmed: 22476947
World J Clin Oncol. 2019 Jun 24;10(6):222-233
pubmed: 31367531
Phys Biol. 2011 Feb;8(1):015008
pubmed: 21301062
Trends Pharmacol Sci. 2015 Jul;36(7):461-70
pubmed: 26022934
Int Immunopharmacol. 2021 Jan;90:107158
pubmed: 33187910
Am J Cancer Res. 2017 Mar 01;7(3):574-583
pubmed: 28401013
J Exp Clin Cancer Res. 2020 Aug 12;39(1):156
pubmed: 32787888
Nat Commun. 2016 Jan 12;7:10230
pubmed: 26756352
Cancer Res. 2005 Dec 1;65(23):10862-71
pubmed: 16322233
Front Physiol. 2020 Jan 29;10:1607
pubmed: 32063863
Arch Gynecol Obstet. 2022 Oct;306(4):1185-1195
pubmed: 35249152
Pharmacol Ther. 2020 Feb;206:107451
pubmed: 31836453
Breast Cancer (Auckl). 2020 Jan 10;14:1178223419898458
pubmed: 31975779
NPJ Breast Cancer. 2021 Mar 26;7(1):36
pubmed: 33772015
Cancer Res. 2002 Jun 15;62(12):3417-27
pubmed: 12067984
J Clin Pathol. 2021 Sep;74(9):571-576
pubmed: 32848015
Cytokine. 2019 Aug;120:155-164
pubmed: 31085453
Clin Cancer Res. 2005 Aug 1;11(15):5390-5
pubmed: 16061852
Mol Clin Oncol. 2017 Dec;7(6):935-942
pubmed: 29285353
Chem Res Toxicol. 2020 Feb 17;33(2):482-491
pubmed: 31876149
Breast Cancer Res Treat. 2010 Jun;121(2):293-300
pubmed: 19597705
Front Biosci (Landmark Ed). 2013 Jan 01;18(1):133-44
pubmed: 23276914
Clin Cancer Res. 2016 Sep 1;22(17):4478-90
pubmed: 27036136
Cell Signal. 2020 Oct;74:109731
pubmed: 32758668
Zhonghua Bing Li Xue Za Zhi. 2018 Oct 8;47(10):743-746
pubmed: 30317727
Int J Cancer. 2012 Sep 1;131(5):1023-31
pubmed: 22038895
Medicine (Baltimore). 2018 Jul;97(29):e11433
pubmed: 30024516
Mol Oncol. 2008 Oct;2(3):223-32
pubmed: 19383343
PLoS One. 2013 Aug 22;8(8):e73183
pubmed: 23991180
Adv Med Sci. 2022 Mar;67(1):170-178
pubmed: 35290873
Nat Med. 2011 Oct 30;17(11):1498-503
pubmed: 22037646
Mol Metab. 2014 Mar 22;3(4):384-93
pubmed: 24944898
Annu Rev Physiol. 2008;70:537-56
pubmed: 17937601
Sci Rep. 2021 May 10;11(1):9922
pubmed: 33972642
J Agric Food Chem. 2005 May 18;53(10):3751-68
pubmed: 15884793
Int J Mol Sci. 2019 May 22;20(10):
pubmed: 31121868
Endocr Relat Cancer. 2011 Jul 11;18(4):491-503
pubmed: 21636700
Breast Cancer Res. 2011 Mar 30;13(2):R34
pubmed: 21450081
Int J Oncol. 2012 Sep;41(3):959-68
pubmed: 22766682
J Cell Mol Med. 2020 Sep;24(17):10233-10244
pubmed: 32681609
Endocrinology. 2003 Sep;144(9):3765-73
pubmed: 12933646
Oncogene. 2017 Jul 13;36(28):4001-4013
pubmed: 28288136
Eur J Cancer. 2011 Jul;47(10):1578-84
pubmed: 21353530
CA Cancer J Clin. 2017 Sep;67(5):378-397
pubmed: 28763097
FEBS J. 2021 Dec;288(24):6850-6912
pubmed: 33605520
Nat Rev Cancer. 2004 Aug;4(8):579-91
pubmed: 15286738
Endocr Relat Cancer. 2013 Oct 14;20(6):797-808
pubmed: 24025407
Autophagy. 2017 Aug 3;13(8):1386-1403
pubmed: 28696138
Eur J Clin Invest. 2008 Jun;38(6):438-46
pubmed: 18452545
Sci Transl Med. 2015 Aug 19;7(301):301ra130
pubmed: 26290412
Front Endocrinol (Lausanne). 2021 May 18;12:585887
pubmed: 34084149
Diabetologia. 2015 Jul;58(7):1579-86
pubmed: 25952479
Expert Opin Ther Targets. 2014 Aug;18(8):883-95
pubmed: 24899149
Horm Mol Biol Clin Investig. 2015 Jan;21(1):43-56
pubmed: 25781551
J Cell Biochem. 2007 Nov 1;102(4):912-24
pubmed: 17910028
Cancer Cell Int. 2018 Feb 09;18:19
pubmed: 29449787
Neoplasia. 2017 Aug;19(8):649-658
pubmed: 28732212
Oncogene. 2018 Feb 1;37(5):589-600
pubmed: 28991224
Gene. 2017 Jul 20;621:51-58
pubmed: 28414093
Breast Cancer Res Treat. 2011 Nov;130(2):587-97
pubmed: 21667121
Int J Mol Sci. 2020 Apr 20;21(8):
pubmed: 32325994
N Engl J Med. 2016 Aug 25;375(8):794-8
pubmed: 27557308
Pulm Circ. 2020 Sep 18;10(3):2045894020952019
pubmed: 32999709
Clin Endocrinol (Oxf). 2015 Aug;83(2):147-56
pubmed: 25393563
J Hematol Oncol. 2019 Sep 10;12(1):95
pubmed: 31500658
J Cell Physiol. 2006 Apr;207(1):12-22
pubmed: 16110483
Nat Rev Endocrinol. 2014 Aug;10(8):455-465
pubmed: 24935119
Endocr Rev. 2012 Aug;33(4):547-94
pubmed: 22547160
Trends Cancer. 2020 Jul;6(7):593-604
pubmed: 32610069
Pathol Oncol Res. 2021 Sep 13;27:1609828
pubmed: 34588926
BJU Int. 2011 Jul;108(2 Pt 2):E77-83
pubmed: 21050358
Trends Mol Med. 2021 Oct;27(10):1000-1013
pubmed: 34389240
Acta Pharm Sin B. 2015 Sep;5(5):378-89
pubmed: 26579469
Hum Pathol. 2014 Mar;45(3):504-12
pubmed: 24440093
Sci Rep. 2018 Jun 11;8(1):8859
pubmed: 29891854
Breast Cancer (Dove Med Press). 2018 Oct 23;10:169-176
pubmed: 30498371
Oncogene. 2004 Aug 23;23(38):6365-78
pubmed: 15322511
Expert Opin Ther Targets. 2018 Aug;22(8):727-734
pubmed: 30025479
Front Physiol. 2016 Sep 27;7:430
pubmed: 27729871
Int J Oncol. 2006 Apr;28(4):985-93
pubmed: 16525650
Diabetologia. 2012 Oct;55(10):2811-2822
pubmed: 22798065
Cells. 2020 Apr 18;9(4):
pubmed: 32325700
Carcinogenesis. 2009 Apr;30(4):589-97
pubmed: 19181699
Proc Natl Acad Sci U S A. 2020 Dec 29;117(52):33295-33304
pubmed: 33318171
Breast Cancer Res. 2019 May 22;21(1):67
pubmed: 31118047
Cancer Res. 2014 Feb 1;74(3):862-72
pubmed: 24295734
PLoS One. 2015 Jun 24;10(6):e0129741
pubmed: 26107623
EBioMedicine. 2021 Nov;73:103627
pubmed: 34656878
J Clin Endocrinol Metab. 2013 Dec;98(12):4664-5
pubmed: 24108312
Oncotarget. 2014 Feb 15;5(3):613-33
pubmed: 24327602
Oncotarget. 2016 Apr 26;7(17):24495-509
pubmed: 27027351
Bioengineering (Basel). 2021 Apr 03;8(4):
pubmed: 33916786
Front Endocrinol (Lausanne). 2014 May 01;5:65
pubmed: 24829560
Metabolism. 2018 May;82:72-87
pubmed: 29330025
Mol Oncol. 2021 Oct;15(10):2752-2765
pubmed: 34342930
Int J Mol Sci. 2021 May 25;22(11):
pubmed: 34070254
Diabetes Care. 2015 Feb;38(2):264-70
pubmed: 25488912
Int J Mol Sci. 2020 May 18;21(10):
pubmed: 32443588
Cancer Res. 2011 Apr 1;71(7):2455-65
pubmed: 21459803
Annu Rev Biochem. 2006;75:137-63
pubmed: 16756488
Clin Cancer Res. 2006 Mar 1;12(5):1447-53
pubmed: 16533767
Dis Markers. 2017;2017:4862016
pubmed: 29311755
Int J Mol Sci. 2021 Apr 06;22(7):
pubmed: 33917351
Immunotargets Ther. 2016 May 23;5:47-56
pubmed: 27529061
Cancers (Basel). 2020 Jun 25;12(6):
pubmed: 32630445
Recent Results Cancer Res. 2016;208:155-176
pubmed: 27909907
PLoS One. 2013 Dec 04;8(12):e82460
pubmed: 24324792
Nature. 1994 Dec 1;372(6505):425-32
pubmed: 7984236
Curr Pharm Des. 2017;23(25):3645-3657
pubmed: 28677505
Int J Med Sci. 2021 May 13;18(12):2689-2696
pubmed: 34104101
Mol Metab. 2016 Sep 13;5(11):1131-1137
pubmed: 27818939
J Endocrinol. 2018 Aug;238(2):R79-R94
pubmed: 29848608
Cell Cycle. 2009 Aug;8(15):2347-52
pubmed: 19571677
Breast Cancer Res. 2019 Apr 29;21(1):54
pubmed: 31036052
J Clin Endocrinol Metab. 2001 May;86(5):1930-5
pubmed: 11344187
Maturitas. 2012 Mar;71(3):301-8
pubmed: 22261365
Front Immunol. 2021 Mar 29;11:612013
pubmed: 33854494
Breast Cancer Res. 2018 Jun 14;20(1):54
pubmed: 29898755
Proc Natl Acad Sci U S A. 2012 Jun 19;109(25):9786-91
pubmed: 22665775
Obes Res Clin Pract. 2018 May - Jun;12(3):251-259
pubmed: 29428365
Endocr Relat Cancer. 2015 Dec;22(6):R365-86
pubmed: 26373570
Front Immunol. 2019 May 08;10:983
pubmed: 31139180
Medicine (Baltimore). 2018 Jul;97(27):e11345
pubmed: 29979411
Exp Ther Med. 2017 May;13(5):2235-2246
pubmed: 28565832
Int J Mol Sci. 2020 May 27;21(11):
pubmed: 32471192
Science. 2005 Jan 21;307(5708):426-30
pubmed: 15604363
Breast Cancer Res. 2020 Feb 11;22(1):18
pubmed: 32046756
Vaccines (Basel). 2016 Jul 26;4(3):
pubmed: 27472371
Asian Pac J Cancer Prev. 2014;15(23):10115-9
pubmed: 25556435
Arterioscler Thromb Vasc Biol. 2000 Jun;20(6):1595-9
pubmed: 10845877
Expert Opin Ther Targets. 2018 Nov;22(11):941-953
pubmed: 30332900
Oncogene. 2009 Jul 30;28(30):2745-55
pubmed: 19483720
Gynecol Oncol. 2012 Jun;125(3):742-50
pubmed: 22370603
J Mammary Gland Biol Neoplasia. 2019 Mar;24(1):85-97
pubmed: 30474817
PLoS One. 2017 Mar 23;12(3):e0174126
pubmed: 28333977
Cancer Res. 2008 Dec 1;68(23):9712-22
pubmed: 19047149
Theranostics. 2016 Jan 01;6(1):1-13
pubmed: 26722369
Breast Cancer Res Treat. 2008 Apr;108(3):389-97
pubmed: 17554627
Pharmacol Ther. 2013 May;138(2):197-210
pubmed: 23353703
Arch Pharm Res. 2005 Nov;28(11):1263-9
pubmed: 16350853
Peptides. 2017 Jun;92:9-15
pubmed: 28442350
EMBO Mol Med. 2012 Oct;4(10):1087-96
pubmed: 22933245
Front Oncol. 2020 Mar 17;10:306
pubmed: 32257945
Cell Immunol. 2010;265(1):80-5
pubmed: 20705284
Expert Rev Anticancer Ther. 2016 Aug;16(8):827-38
pubmed: 27186719
Breast Cancer Res Treat. 2003 Jul;80(1):71-8
pubmed: 12889600
J Natl Cancer Inst. 2015 Sep 30;107(12):djv275
pubmed: 26424778
Oncogene. 2007 Dec 6;26(55):7692-9
pubmed: 17563744
Sci Rep. 2016 Jan 05;6:18923
pubmed: 26729407
Cancers (Basel). 2019 Jan 09;11(1):
pubmed: 30634494
BMC Cancer. 2018 May 31;18(1):616
pubmed: 29855282
Endocr Relat Cancer. 2012 Sep 05;19(5):F27-45
pubmed: 22593429
Front Endocrinol (Lausanne). 2020 Feb 18;11:66
pubmed: 32132979
Circulation. 2004 Nov 23;110(21):3335-40
pubmed: 15545519
Transl Oncol. 2021 Oct;14(10):101178
pubmed: 34293684
Oncotarget. 2014 Jul 15;5(13):5087-99
pubmed: 24970818
Int J Mol Med. 2015 Sep;36(3):733-8
pubmed: 26135903
Am J Physiol Endocrinol Metab. 2001 Jun;280(6):E827-47
pubmed: 11350765
Curr Obes Rep. 2019 Dec;8(4):413-433
pubmed: 31637624
Mol Carcinog. 2012 Nov;51(11):861-8
pubmed: 21882260
DNA Cell Biol. 1994 Dec;13(12):1189-97
pubmed: 7811385
Oncotarget. 2016 Sep 6;7(36):57694-57704
pubmed: 27509174
Nature. 2001 Jan 18;409(6818):307-12
pubmed: 11201732
Cancer Epidemiol Biomarkers Prev. 2011 Sep;20(9):1892-901
pubmed: 21784959